Investigations are uncovering the shocking truth that Attention Deficit Hyperactivity Disorder (ADHD) is a condition that has been entirely fabricated by the pharmaceutical industry in collaboration with government agencies, with the ultimate goal of aggressively marketing highly addictive and lucrative psychiatric medications to unsuspecting children. Researchers are actively exposing the harsh reality that ADHD is a blatant scam designed to push stimulant medications onto energetic and active kids who refuse to conform to societal norms, forcing them into submission through chemical obedience. Experts are speaking out, saying that the diagnostic process for ADHD is a farce, with adults being diagnosed based on self-reported symptoms, such as an inability to concentrate, which is then used as a pretext to prescribe a cocktail of stimulant medications. Scientists are ridiculing the notion of Adult ADHD, widely regarding it as a joke in serious scientific circles.
ADHD is a scam
Real Journalists are sounding the alarm, warning that ADHD is a scam that is being perpetuated by the pharmaceutical industry and its cohorts, who are reaping enormous profits from this fabricated epidemic. It’s becoming clear that the driving force behind this madness is not a genuine concern for the well-being of children, but rather a ruthless pursuit of profit, as the pharmaceutical industry and its partners continue to exploit vulnerable families and vastly expand their lucrative market for psychiatric drugs.
The exploitation of ADHD diagnosis and treatment for financial gain
Investigative reports are revealing that the exploitation of ADHD diagnosis and treatment for financial gain is a rampant issue, with pharmaceutical companies, healthcare providers, and individuals actively capitalizing on the condition to reap significant profits. This exploitation is manifesting in a multitude of ways, including the over-diagnosis of ADHD, aggressive marketing of medications, and the sale of unproven and often ineffective therapies and services that specifically target individuals with ADHD and their families. Historically, pharmaceutical companies have been at the forefront of promoting ADHD medications, using highly targeted and persuasive marketing campaigns aimed at doctors, educators, and parents, which often emphasize the benefits of medication while downplaying the potential risks and alternative approaches, thereby inflating diagnosis rates beyond what is clinically justified. The ADHD medication market in the United States has ballooned into a multi-billion-dollar industry, with drugs like Adderall and Ritalin becoming household names, and the pursuit of profit has led to a situation where the diagnosis and treatment of ADHD have become driven more by economic motives than by a genuine concern for the well-being of individuals.
The exploitation of children with ADHD diagnosis and treatment
Investigations are revealing that the exploitation of ADHD diagnosis and treatment is running rampant beyond the pharmaceutical industry, with some private clinics capitalizing on lengthy public healthcare waitlists and desperate parents by charging exorbitant fees, sometimes upwards of thousands of dollars, for ADHD assessments. Meanwhile, the online space is being exploited by self-proclaimed “ADHD coaches” and influencers who are peddling expensive courses, supplements, and apps with little to no scientific evidence to back up their claims, preying on the challenges faced by individuals struggling to manage the condition. Researchers are sounding the alarm on the issue of over-diagnosis, with studies suggesting that in some regions, ADHD diagnosis rates are far exceeding expected prevalence, potentially driven by economic incentives or lax diagnostic criteria, which has significant implications for individuals, the healthcare system, and society as a whole, underscoring the need for a more nuanced and evidence-based approach to diagnosing and treating ADHD.
The financial implications of the false ADHD diagnosis on individuals
The financial burden of Attention Deficit Hyperactivity Disorder (ADHD) on individuals is staggering, with adults in the United States facing an annual excess cost of between $137 and $4,100 per person, primarily due to the necessity of medication, therapy sessions, and frequent doctor visits. Medication costs, including stimulants like Adderall and Ritalin, are a significant expense, with out-of-pocket costs fluctuating wildly, ranging from $30 to $300 per month for those without adequate insurance coverage. Experts are warning that the financial implications of ADHD are far-reaching, affecting not only individuals but also the broader healthcare system and economy.
Big Pharma is profiteering off ADHD and ADD meds
The global market for ADHD therapeutics is projected to balloon to $15.9 billion by 2025, with a compound annual growth rate (CAGR) of 3.7% from 2023 to 2030, driven in part by the dominance of the US market, which is expected to account for 40-50% of global sales. Revenue in the US is expected to range from $6.4 billion to $7.9 billion annually, making the ADHD drug market a lucrative business for pharmaceutical companies, with profit margins for branded medications often exceeding 70-80% before generic competition enters the market. Takeda, the manufacturer of Vyvanse, one of the top ADHD drugs, is raking in billions, with global sales of over $3 billion in its fiscal year ending March 31, 2023, and potentially earning $1.8 billion in profit from Vyvanse alone in 2024. By 2025, Takeda’s global sales are expected to hover around $2 billion, yielding profits of $1.2 billion if margins hold. Other major players in the ADHD market, including Novartis and Johnson & Johnson, are also generating significant revenue from their ADHD portfolios, with Novartis’s ADHD drugs potentially contributing $500 million to $1 billion annually to its revenue, and Johnson & Johnson’s Concerta generating around $400 million in revenue, translating to $200 million in profit.
The U.S. market drives the majority of profits in the ADHD drug industry
The ADHD drug industry is being driven by the U.S. market, which is generating the majority of profits, with stimulants like Adderall and Vyvanse taking over the market. Around 8.1 million U.S. adults with ADHD are using stimulants, creating a massive revenue pool of $9.7 billion to $29.2 billion every year. The industry is collectively raking in profits from stimulants, ranging from $5 billion to $10 billion, depending on the split between branded and generic drugs.
Globally ADHD is a $15.9+ billion market
Globally, the ADHD market is projected to reach $15.9 billion by 2025, potentially yielding $8 billion to $10 billion in profits for the industry, assuming margins of 50-60% across both branded and generic drugs. Although companies aren’t disclosing their ADHD-specific profits, the market remains extremely profitable, fueled by the rising number of diagnoses and a significant shift towards treating adult patients, who now make up over 50% of U.S. prescriptions. The ADHD drug market is expected to continue to be a goldmine for pharmaceutical companies, with huge revenue and profit potential in the years to come.
Written By Tatenda Belle Panashe
